Lorazepam has an elimination half-life that typically falls between 8 and 25 hours, meaning it takes roughly two to three days for a single dose to clear from your bloodstream almost entirely. But “lasting in your system” and “showing up on a drug test” are two different questions with different timelines. Urine tests can detect lorazepam or its breakdown products for about six days after a single dose, and the answer shifts further depending on your age, body size, other medications, and the type of test being used.
Half-Life and What It Actually Means for You
The half-life of a drug is the time it takes for your body to reduce the amount in your blood by half. For lorazepam, that range is about 8 to 25 hours, with most people landing somewhere in the middle around 12 to 18 hours.1PubMed. Clinical pharmacokinetics of oxazepam and lorazepam After one half-life, half the drug is gone. After two, a quarter remains. After about five half-lives, the drug is considered effectively eliminated. For someone with a half-life of 15 hours, that works out to roughly three days. For someone on the longer end, closer to five days.
This does not mean you feel the drug’s effects for three to five days. The calming and sedating effects of a typical dose wear off well before the drug has fully cleared. Most people notice the anxiolytic effect fading after about six to eight hours, though residual drowsiness or mental sluggishness can linger longer, especially at higher doses or in people who are particularly sensitive. The distinction matters because your body is still processing lorazepam long after you stop feeling it.
How Your Body Breaks Down Lorazepam
Unlike many benzodiazepines that go through a complicated series of chemical transformations in the liver, lorazepam follows a relatively straightforward path. The liver attaches a molecule called glucuronic acid to the drug, creating an inactive compound called lorazepam glucuronide. That inactive compound then gets flushed out through your kidneys in urine.1PubMed. Clinical pharmacokinetics of oxazepam and lorazepam The enzymes responsible for this step belong to a family called UGTs, with UGT2B7 and UGT2B15 doing most of the work.2PubMed. The glucuronidation of R- and S-lorazepam: human liver microsomal kinetics, UDP-glucuronosyltransferase enzyme selectivity, and inhibition by drugs
This simpler metabolic route is one reason doctors sometimes prefer lorazepam for people with liver problems. Because the drug skips the complex oxidation steps that other benzodiazepines require, it puts less strain on an already compromised liver. The glucuronide it produces is inactive and nontoxic, so it does not create secondary effects as it waits to be excreted.
How Long Lorazepam Shows Up on Drug Tests
The detection window depends on what kind of test is being run and how sensitive it is.
In urine, lorazepam can be detected for about six days (144 hours) after a single dose. Concentrations peak roughly 24 hours after ingestion and then taper off gradually over the following days.3PubMed. Windows of detection of lorazepam in urine, oral fluid and hair, with a special focus on drug-facilitated crimes At the tail end of that window, the concentrations are very low, in the range of just a few nanograms per milliliter, so whether a test catches them depends on its sensitivity threshold.
Blood (or serum/plasma) tests have a shorter detection window than urine, generally a few days at most. Advanced lab techniques can pick up concentrations as low as about 0.1 nanograms per milliliter, which extends the window slightly.4PubMed. A fast and sensitive liquid chromatographic-tandem mass spectrometric method for assay of lorazepam and application to pharmacokinetic analysis Hair testing is a different story entirely. Hair tests can detect benzodiazepine use over weeks or months, though they are used far less often in routine screening.
For people taking lorazepam daily rather than as a single dose, the detection window stretches. When you take a drug repeatedly, each new dose arrives before the previous one has fully cleared, so concentrations build up. Research on repeated daily dosing found that lorazepam reaches a steady level in the body within several days, with drug levels roughly doubling compared to a single dose.5PubMed. Single- and multiple-dose kinetics of oral lorazepam in humans: the predictability of accumulation After stopping a daily regimen, it will take longer for concentrations to drop below the detection threshold than it would after a single dose.
Why Standard Drug Screens Can Miss Lorazepam
If you are wondering whether a standard workplace or emergency-room urine screen will pick up lorazepam, the answer is: not always. Most routine drug panels use an immunoassay, which is a quick and cheap test that reacts to a broad class of benzodiazepine-related compounds. The trouble is that lorazepam and its metabolite do not trigger these assays as reliably as some other benzodiazepines do. Even newer immunoassay formulations with improved sensitivity for lorazepam still missed about 27% of specimens that tested positive on the more precise confirmation method (mass spectrometry).6Journal of Mass Spectrometry and Advances in the Clinical Lab. Despite the improved clinical sensitivity of the Roche benzodiazepines II assay it cannot replace mass spectrometry in all patient populations
This has real-world consequences. A false negative on a compliance monitoring test might incorrectly suggest someone is not taking their prescribed medication. In a forensic or emergency setting, a missed result could mean a lorazepam exposure goes undetected. If precise detection matters, the gold-standard approach is a confirmatory test using mass spectrometry, which identifies the specific drug and its metabolites at much lower concentrations.
Age, Weight, and Other Factors That Shift the Timeline
Several personal characteristics influence how quickly your body clears lorazepam, though the effects are sometimes smaller than you might expect.
Age
Older adults clear lorazepam somewhat more slowly, but the difference is modest. In one study comparing elderly and younger subjects, the elimination half-life was about 16 hours in the elderly group versus 14 hours in the younger group, a gap that was not statistically meaningful. However, total clearance was about 22% lower in the older group.7PubMed. Lorazepam kinetics in the elderly Part of that difference was explained by the fact that more of the younger subjects smoked cigarettes, which tends to speed up drug metabolism. For practical purposes, the drug may linger somewhat longer in older adults, but the effect is less dramatic than it is for many other benzodiazepines. This is actually one reason lorazepam is sometimes chosen over longer-acting options in older patients.
Body Weight and Obesity
Lorazepam distributes into body fat, so people with higher body weight carry a larger total amount of the drug in their system after a dose. In obese individuals, the absolute volume of distribution nearly doubled compared to people of normal weight. But here is the thing that surprises many people: the elimination half-life was not meaningfully different between obese and non-obese subjects (roughly 16.5 versus 15 hours). That is because clearance also increased proportionally with body weight.8PubMed. Enhanced glucuronide conjugation of drugs in obesity: studies of lorazepam, oxazepam, and acetaminophen A broader review of drug metabolism in obesity confirmed that for many drugs, including lorazepam, the prolonged presence people worry about is more about distribution into fat tissue than about the liver struggling to keep up.9PubMed. Drug Disposition in Subjects With Obesity: The Research Work of Darrell R. Abernethy
Kidney Disease
Since the inactive lorazepam glucuronide exits through the kidneys, you might assume kidney problems would be a big deal. In practice, the effect is limited. A study of patients with kidney impairment found that the clearance of lorazepam itself (the step happening in the liver) was not significantly different from that in healthy subjects. The inactive metabolite may accumulate in the blood, but because it has no pharmacological activity, this buildup does not appear to cause harm. The researchers concluded that no dosage adjustment is needed for kidney disease alone.10PubMed. Effect of renal impairment and hemodialysis on lorazepam kinetics
Pregnancy
Pregnancy speeds things up rather than slowing them down. Research on pregnant women found that the apparent clearance of lorazepam increased and the half-life shortened to around 10 hours, likely because the glucuronidation process becomes more active during pregnancy.11PubMed. Kinetic disposition of lorazepam with focus on the glucuronidation capacity, transplacental transfer in parturients and racemization in biological samples That said, lorazepam does cross the placenta. The concentration in umbilical cord blood averaged about 73% of the mother’s blood concentration in that same study. Compared to diazepam, lorazepam appears to cross the placenta more slowly, though the clinical meaning of that difference is still debated.12PubMed. Use of benzodiazepines during pregnancy, labour and lactation, with particular reference to pharmacokinetic considerations
Medications That Slow Lorazepam’s Clearance
Because lorazepam depends so heavily on glucuronidation, any drug that interferes with that enzyme pathway can cause lorazepam to hang around longer. The best-studied example is valproic acid (brand names Depakote, Depakene), a medication widely used for seizures, bipolar disorder, and migraine prevention. When valproic acid is taken alongside lorazepam, it reduces lorazepam’s clearance by about 31%, leading to higher blood levels and a longer effective presence in the body.13PubMed. Effect of valproate on the pharmacokinetics and pharmacodynamics of lorazepam This combination is common in clinical practice, especially in patients being treated for seizures, which makes the interaction clinically relevant rather than merely theoretical.
Other medications and substances that inhibit UGT enzymes could theoretically have similar effects, though the evidence for specific interactions is less robust than for valproic acid. Probenecid, for example, is known to inhibit glucuronidation broadly and has been flagged as a potential interactor. The practical takeaway is that if you are taking other medications, your doctor should be evaluating whether any of them could slow lorazepam’s metabolism.
Do Your Genes Matter?
Pharmacogenomics, the study of how genetic variation affects drug metabolism, has gotten a lot of attention in recent years for many medications. For lorazepam, the story is underwhelming. Researchers looked at whether genetic variants in the UGT2B7 enzyme (one of the primary enzymes that processes lorazepam) affected how quickly people cleared the drug. The result: no significant differences in lorazepam clearance based on UGT2B7 genotype were found.14PubMed Central. Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects There were hints that genetics might play a role in how the body responds when lorazepam is combined with valproic acid, but on its own, lorazepam’s clearance does not appear to be strongly driven by known genetic variants. This is an area where the evidence is still thin, but for now, genetic testing is unlikely to change how your doctor prescribes lorazepam.
Withdrawal and What Happens When You Stop
How long lorazepam stays in your system is often a concern not because of drug testing, but because people want to know when withdrawal symptoms might start. Withdrawal from benzodiazepines generally begins as blood levels drop, and lorazepam is among the benzodiazepines more likely to cause withdrawal symptoms compared to some others in its class.15Karger Publishers (“Psychotherapy and Psychosomatics”). Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications
For someone who has been taking lorazepam daily, early withdrawal symptoms like increased anxiety, insomnia, and irritability can appear within 24 to 48 hours of the last dose, roughly when blood levels have dropped to a fraction of their steady-state concentration. Lorazepam’s intermediate half-life places it in a tricky middle ground: it is not so long-acting that the taper happens gradually on its own (the way it might with a very long-acting benzodiazepine), and it is not so short-acting that withdrawal hits within hours. Doctors often manage this by slowly reducing the dose over weeks or by switching to a longer-acting benzodiazepine to create a smoother taper.
The severity of withdrawal depends heavily on how long you have been taking the drug, at what dose, and individual biology. Someone who has used lorazepam daily for months or years faces a much more significant withdrawal than someone who took it for a week. This is not the kind of medication to stop abruptly without medical guidance, regardless of how quickly it clears your system.
Pediatric Differences
Children process lorazepam somewhat differently than adults. A pharmacokinetic study in pediatric patients found an average half-life of about 17 hours and a clearance of 1.2 milliliters per minute per kilogram, which falls within the adult range.16PubMed Central. The pharmacokinetics of intravenous lorazepam in pediatric patients with and without status epilepticus The volume of distribution was slightly higher than in adults, suggesting the drug spreads more widely relative to body size. In practice, this means children are not dramatically faster or slower at clearing lorazepam than adults, but dosing is weight-based and clinical monitoring is especially important because the sedating effects can be more pronounced in younger patients.
Lorazepam in Forensic Toxicology
Outside of clinical and drug-testing contexts, lorazepam’s behavior after death presents its own challenges. In forensic cases, toxicologists need to determine what drugs were present and at what concentrations at the time of death. The problem is that many drugs redistribute within the body after death, migrating from organs into the blood and creating artificially elevated or depressed concentrations depending on where the sample is drawn. For lorazepam, research suggests that postmortem redistribution cannot be ruled out, meaning that drug concentrations measured from a postmortem blood sample may not accurately reflect the concentration at the time of death.17PubMed. Evaluation of postmortem redistribution phenomena for commonly encountered drugs This uncertainty complicates forensic interpretations, especially in cases involving suspected overdose or drug-facilitated crimes, where accurate concentration estimates carry legal weight.
Lorazepam has also drawn forensic attention as a drug used in drug-facilitated assaults. Its relatively rapid onset, amnestic properties, and the fact that routine immunoassays can miss it at low concentrations make it a concern in that context. Forensic labs investigating suspected cases typically rely on mass spectrometry to detect trace amounts in urine or blood collected within the first few days, since the detection window at very low concentrations is narrow.